Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Spikevax Filed for Kids Aged 6 to 11 in Japan: Moderna
February 10, 2023
- Takeda Wraps Up Acquisition of Nimbus’ TYK2 Immune Therapy
February 10, 2023
- Sumitomo Sees Sales Force as Asset to Lure Collabs; Rep Cut Not in the Cards though Trulicity Deal Ended
February 9, 2023
- Santen’s Glaucoma Med Tapcom Accepted for Review in China
February 9, 2023
- Masao Hirokawa Named Next President of Fujifilm Kyowa Kirin Biologics
February 9, 2023
- Mitsubishi Tanabe Incurs 33 Billion Yen Operating Loss on Medicago Shutdown
February 8, 2023
- Kyowa Kirin’s Crysvita Crosses Blockbuster Line: 2022 Earnings
February 8, 2023
- Takhzyro Adds Pediatric Indication in US: Takeda
February 8, 2023
- Daiichi Sankyo Espha’s Nexium Generic Hits Japan Market
February 8, 2023
- Japan Ethical Drug Sales Surge 5.8% in December: Crecon
February 8, 2023
- CSL Behring Soon to Launch Home Delivery Service for Hemophilia Therapies
February 8, 2023
- ASKA, Japan Biotech Strike R&D Deal to Create VHH Therapies in OB-GYN Field
February 8, 2023
- Eisai Alzheimer’s Chief Says Lecanemab US Sales “Ahead of Expectations”
February 7, 2023
- Next Astellas CEO Says Weathering Xtandi Cliff Is His Biggest Mission
February 7, 2023
- Teijin Pharma Picks R&D Chief Taneda for President from April
February 7, 2023
- Mochida Abandons Antidepressant MD-120, Lexapro’s Pediatric Use
February 7, 2023
- Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
- Eisai’s 9-Month Profits Sink after One-Time BMS Alliance Gain a Year Ago
February 7, 2023
- Opdivo Extends Streak of Top-Seller Crown to 13 Months: Encise
February 7, 2023
- Astellas EVP Okamura to Become CEO in April
February 6, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…